Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens

Sanguine Biosciences

Status: Withdrawn

Conditions: Colorectal Cancer

Treatments: Other: Stool Collection and Survey Completion

Study type: Observational

Funder types: Industry

Identifiers

NCT05821582

SAN-09391

Details and patient eligibility

About

The primary objective of the study is to determine whether there is a correlation between the intestinal side effects of chemotherapy treatment and the expression/activity profiles of glucuronidase enzymes in the stool microbiome of the target patient population.

Full description

STUDY DESIGN:

• This protocol is a single-center, single-cohort, bioresearch study enrolling up to 8 participants. The cohort is as follows:
• Cohort 1: Colorectal Cancer: (n=8)
• The study will enroll participants per the eligibility criteria.
• Participants will have 2 scheduled at-home stool self-collections at the time points specified in section 4.0 and complete a questionnaire by telephone contact (see section 11.0 for details). The biospecimens collected from participants on this study are stool samples.
• Confirmation of eligibility and medical record review by a member of the study staff will be completed for participants of the disease cohort before they are considered fully enrolled.

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Cohort 1: Colorectal Cancer

Inclusion:

1. The participant is willing and able to provide written informed consent
2. The participant is willing and able to provide appropriate photo identification
3. Participants aged 18 to 85, Inclusive
4. Participants have been diagnosed with Active Colorectal Cancer (CRC)
5. Subjects currently taking irinotecan

Exclusion:

1. Participants who are pregnant or are nursing

2. Participants with a known history of HIV, hepatitis, or other infectious diseases

3. Participants who have taken an investigational product in the last 30 days

4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months

5. Subjects who are currently in remission for CRC.

   • Preference (not required for enrollment into study): Exclude subjects currently taking antibiotics*